Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
Globe Newswire•05/08/2026•07:30 ET
0
Whiz Insights
- 17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib in combination with chemotherapy, reported in oral presentation at ASCO Annual Meeting on June 1 -
- Phase 3 MAPKeeper 301 trial is underway, with patients being dosed and over 30 study locations posted to date -
Get started
Create a free account to read the full story.